Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 54, Issue 17, Pages 6050-6062Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm2005354
Keywords
-
Categories
Ask authors/readers for more resources
Structure based design led directly to 1,3-oxazinan-2-one 9a with an IC50 of 42 nM against 11 beta-HSD1 in vitro. Optimization of 9a for improved in vitro enzymatic and cellular potency afforded 25f with IC50 values of 0.8 nM for the enzyme and 2.5 nM in adipocytes. In addition, 25f has 94% oral bioavailability in rat and >1000 x selectivity over 11 beta-HSD2. In mice, 251 was distributed to the target tissues, liver, and adipose, and in cynomolgus monkeys a 10 mg/kg oral dose reduced cortisol production by 85% following a cortisone challenge.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available